细胞周期标志物p53、MDM2、p21和Ki-67在浅表性膀胱肿瘤复发中的预测价值
Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
作者信息
Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y
机构信息
Centre de Recherche en Cancérologie, Université de Laval, Québec, Canada.
出版信息
Clin Cancer Res. 1999 Dec;5(12):4079-84.
The aim of the study was to determine whether the expression of the cell cycle markers p53, MDM2, p21, and Ki-67 was predictive of superficial bladder cancer recurrence and to compare the relative predictive power for tumor recurrence of a cell cycle index based on the number of abnormally expressed cell cycle markers with a clinicopathological index based on primary clinical tumor characteristics. The expression of p53, MDM2, and p21 proteins and the value of the Ki-67 index were analyzed for 244 patients. One hundred ninety-four lesions were determined to be superficial papillary tumors (pTa), whereas 50 tumors invaded the lamina propria (pT1). Tumor grade was noted low (grade 1) in 83 cases and high (grades 2-3) in 161 cases. An avidin-biotin peroxidase method was performed using monoclonal antibodies against p53, MDM2, p21, and Ki-67 antigens after antigen retrieval treatment of formalin-fixed specimens. The cell cycle marker index was created using the number of abnormally expressed cell cycle markers according to the following cutoff points: p53 (>5%), MDM2 (>20%), p21 (<5%), and Ki-67 (>10%). The clinicopathological index was created using the following adverse tumor characteristics: grades G2-G3, stage pT1, multifocality, and diameter of tumors > 3 cm. Cox regression models were used to calculate the relative risks and their 95% confidence intervals associated with disease recurrence for the clinicopathological index and the cell cycle marker index. The chi2 test was performed to describe the correlation between the Ki-67 index and p53, MDM2, and p21 protein expression. Kaplan-Meier survival curves were generated to demonstrate the disease-free survival according to these two prognostic indexes. The clinicopathological index was a strong, independent predictor of disease recurrence where tumors with three or four adverse tumor characteristics at initial resection had over four times the risk of recurrence than tumors with no risk factors (P for trend = 0.0001). A strong correlation was observed between the Ki-67 index >10% and both MDM2 and p21 proteins. MDM2 was overexpressed in 106 tumors (43%), and p53 was overexpressed in 47 (19%); Ki-67 was >10% in 171 cases (70%). Thirty-nine tumors (16%) were p21 negative. The risk of recurrence increased slightly with the number of abnormally expressed cell cycle markers, but when the clinicopathological index was taken into account in multivariate analysis, the cell cycle marker index was not predictive of disease recurrence (P for trend = 0.72). The cell cycle markers studied provided no added prognostic information on disease recurrence after initial resection of papillary superficial tumors when the clinicopathological parameters were taken into account.
本研究的目的是确定细胞周期标志物p53、MDM2、p21和Ki-67的表达是否可预测浅表性膀胱癌复发,并比较基于异常表达的细胞周期标志物数量的细胞周期指数与基于原发性临床肿瘤特征的临床病理指数对肿瘤复发的相对预测能力。分析了244例患者的p53、MDM2和p21蛋白表达及Ki-67指数值。194个病变被确定为浅表乳头状瘤(pTa),而50个肿瘤侵犯固有层(pT1)。83例肿瘤分级为低级别(1级),161例为高级别(2 - 3级)。对福尔马林固定标本进行抗原修复处理后,使用针对p53、MDM2、p21和Ki-67抗原的单克隆抗体进行抗生物素蛋白-生物素过氧化物酶法检测。根据以下临界值,使用异常表达的细胞周期标志物数量创建细胞周期标志物指数:p53(>5%)、MDM2(>20%)、p21(<5%)和Ki-67(>10%)。使用以下不良肿瘤特征创建临床病理指数:G2 - G3级、pT1期、多灶性和肿瘤直径>3 cm。使用Cox回归模型计算临床病理指数和细胞周期标志物指数与疾病复发相关的相对风险及其95%置信区间。进行chi2检验以描述Ki-67指数与p53、MDM2和p21蛋白表达之间的相关性。生成Kaplan-Meier生存曲线以根据这两个预后指标展示无病生存期。临床病理指数是疾病复发的有力独立预测指标,初始切除时具有三个或四个不良肿瘤特征的肿瘤复发风险是无危险因素肿瘤的四倍多(趋势P = 0.0001)。观察到Ki-67指数>10%与MDM2和p21蛋白之间存在强相关性。106个肿瘤(43%)中MDM2过表达,47个(19%)中p53过表达;171例(70%)中Ki-67>10%。39个肿瘤(16%)p21阴性。复发风险随异常表达的细胞周期标志物数量略有增加,但在多变量分析中考虑临床病理指数时,细胞周期标志物指数不能预测疾病复发(趋势P = 0.72)。当考虑临床病理参数时,所研究的细胞周期标志物在乳头状浅表肿瘤初始切除后对疾病复发没有提供额外的预后信息。